Zenas BioPharma (NASDAQ:ZBIO) Price Target Cut to $41.00 by Analysts at Citigroup

Zenas BioPharma (NASDAQ:ZBIO) had its target price trimmed by Citigroup from $43.00 to $41.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other analysts also recently commented on the company. Jefferies Financial Group reaffirmed a “buy” rating and set a $48.00 price target on shares of Zenas BioPharma in a research report on Tuesday, January 6th. HC Wainwright reissued a “buy” rating and issued a $44.00 price objective on shares of Zenas BioPharma in a research report on Tuesday. Wall Street Zen upgraded Zenas BioPharma from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. Morgan Stanley raised their target price on Zenas BioPharma from $19.00 to $21.00 and gave the company an “equal weight” rating in a research report on Tuesday. Finally, Evercore started coverage on Zenas BioPharma in a research note on Wednesday, November 26th. They set an “outperform” rating and a $55.00 target price on the stock. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $44.14.

Zenas BioPharma Stock Up 1.1%

Zenas BioPharma stock opened at $23.48 on Tuesday. Zenas BioPharma has a fifty-two week low of $6.11 and a fifty-two week high of $44.60. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.66 and a current ratio of 5.66. The firm’s 50-day simple moving average is $22.78 and its 200 day simple moving average is $27.18. The stock has a market cap of $1.26 billion, a PE ratio of -3.01 and a beta of -1.94.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings data on Monday, March 16th. The company reported ($4.54) EPS for the quarter, missing the consensus estimate of ($1.22) by ($3.32).

Insider Activity at Zenas BioPharma

In other news, Director Hongbo Lu bought 25,985 shares of the firm’s stock in a transaction on Wednesday, February 11th. The stock was acquired at an average cost of $22.50 per share, with a total value of $584,662.50. Following the completion of the transaction, the director directly owned 347,968 shares of the company’s stock, valued at $7,829,280. This represents a 8.07% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Leon O. Moulder, Jr. bought 57,000 shares of the stock in a transaction on Monday, February 2nd. The stock was purchased at an average price of $17.96 per share, for a total transaction of $1,023,720.00. Following the completion of the purchase, the chief executive officer owned 423,155 shares of the company’s stock, valued at approximately $7,599,863.80. This trade represents a 15.57% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have bought 202,845 shares of company stock worth $3,747,185. Insiders own 16.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ZBIO. GF Fund Management CO. LTD. bought a new stake in Zenas BioPharma in the 4th quarter valued at about $38,000. Quarry LP boosted its position in Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after purchasing an additional 291 shares during the period. Russell Investments Group Ltd. bought a new position in Zenas BioPharma during the third quarter worth about $30,000. CWM LLC increased its stake in shares of Zenas BioPharma by 48.3% in the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock worth $79,000 after purchasing an additional 709 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Zenas BioPharma in the fourth quarter valued at approximately $95,000.

Key Headlines Impacting Zenas BioPharma

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: Company secured up to $250M of non-dilutive, multi‑tranche debt financing and reiterated near-term regulatory milestones (FDA filing for obexelimab expected Q2 2026; EMA H2 2026), which supports liquidity and near-term value drivers. Read More.
• Positive Sentiment: Bullish analyst activity: Citigroup cut its price target slightly (to $41) but kept a Buy rating, and HC Wainwright reaffirmed Buy with a $44 target — both signal continued upside expectations from some sell‑side desks and likely helped intraday buying. Read More.
• Positive Sentiment: Insider buying and institutional accumulation highlighted in recent data — sustained insider purchases and notable increases from institutional holders suggest conviction from insiders and some large investors. Read More.
• Neutral Sentiment: Inducement grants: the company granted 235,700 options and 33,450 RSUs to new hires to aid recruitment — supports growth plans but introduces potential future dilution as grants vest. Read More.
• Neutral Sentiment: Morgan Stanley moved its price target up to $21 but kept an Equal Weight/Hold stance — a mixed signal that marginally improves analyst outlook yet sits below the current market price. Read More.
• Negative Sentiment: Major earnings miss: Zenas reported GAAP EPS of -$4.54 vs. consensus -$1.22, a significant shortfall that raises near-term profitability and execution concerns and pressures valuation. Read More.
• Negative Sentiment: Legal risk: disclosure of an IPO‑related securities class action remains an ongoing financial and operational risk that could create litigation cost and distraction. Read More.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.